Chinese Aesthetic Filler Giant Imeik Plans to Acquire REGEN Biotech

On March 10, Imeik announced plans to acquire South Korean peer REGEN Biotech through its wholly-owned subsidiary, Imeik (HK) Limited, as part of its international expansion efforts.

Following the announcement, Imeik's stock surged 8.38% to RMB 189.55 per share at the market open on March 11.

This acquisition marks Imeik's first cross-border deal since its IPO. Under the agreement, Imeik (HK) Limited will partner with Aisheng Shourui (HK) Limited to establish Imeik International, which will acquire an 85% stake in REGEN Biotech for $190 million. Imeik (HK) Limited will own a 70% stake in Imeik International, while Aisheng Shourui (HK) Limited will hold the remaining 30%. The transaction is pending regulatory approval.

Founded in 2000, REGEN Biotech focuses on the development, manufacturing, and sales of medical materials, devices, and pharmaceutical products. The company operates two factories in South Korea and has introduced several approved products, including AestheFill and PowerFill. AestheFill was granted regulatory approval in China in early 2024. In 2023, REGEN Biotech reported revenue of RMB 81.99 million and a net profit of RMB 50.15 million, while its revenue for January–September 2024 reached RMB 72.23 million, with a net profit of RMB 29.50 million.

With an established global distribution network, REGEN Biotech's expertise in international markets will provide valuable support for Imeik's expansion into Europe, North America, Southeast Asia, and the Middle East. Imeik described the acquisition as a key milestone in its global strategy, reinforcing its leadership in the injectable filler market and driving long-term growth.